title: Natural killer cell-dendritic cell crosstalk in the initiation of immune responses.
abstract: Dendritic cells (DCs) and natural killer (NK) cells play a critical role in early defences against cancer and infections. They specialise in complementary functions, including IL-12 or IFN-alpha/beta secretion and antigen presentation for the former, and IFN-gamma secretion and killing of infected or tumour cells for the latter. Both DCs and NK cells are also sensors of the immune system that have developed different, but partially overlapping, systems to identify pathology associated danger signals. Evidence of NK-DC interaction has accumulated recently. This interaction may lead to NK cell activation, DC activation, or apoptosis depending on the activation status of both cell types. Thus, the outcome of NK-DC crosstalk is likely to influence both innate and adaptive immune responses. This review addresses the molecular mechanisms under-lying the different NK-DC interactions, and their in vivo significance in anti-tumour or antimicrobial immunity. Finally, we discuss the potential clinical implications of this new field.
authors.affiliation: 1INSERM-CNRS-Univ, Centre d'Immunologie de Marseille-Luminy, Méditerranée, Campus de Luminy, case 90, 13288 Marseille cedex 09, France.
authors.forename: Thierry
authors.initials: T
authors.lastname: Walzer
authors.forename: Marc
authors.initials: M
authors.lastname: Dalod
authors.forename: Eric
authors.initials: E
authors.lastname: Vivier
authors.forename: Laurence
authors.initials: L
authors.lastname: Zitvogel
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides; D002450:Cell Communication / Q000276:immunology*; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D003713:Dendritic Cells / Q000187:drug effects / Q000201:enzymology / Q000276:immunology*; D004353:Drug Evaluation, Preclinical; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy / Q000201:enzymology / Q000276:immunology; D006566:Herpesviridae Infections / Q000276:immunology; D006801:Humans; D000068877:Imatinib Mesylate; D007694:Killer Cells, Natural / Q000187:drug effects / Q000201:enzymology / Q000276:immunology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000201:enzymology / Q000276:immunology; D008565:Membrane Proteins; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D019009:Proto-Oncogene Proteins c-kit / Q000187:drug effects / Q000378:metabolism; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use; D011971:Receptors, Immunologic / Q000378:metabolism; D015398:Signal Transduction / Q000276:immunology
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000970:Antineoplastic Agents; D001549:Benzamides; D016207:Cytokines; D008565:Membrane Proteins; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011971:Receptors, Immunologic; C110546:TYROBP protein, human; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit